Candel Therapeutics, Inc. Common Stock vs. Moderna, Inc. Common Stock
CADL
Candel Therapeutics, Inc. Common Stock
$13.13 +6.32%
VS MRNAModerna, Inc. Common Stock
$145.13 +8.86%
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| CADL | MRNA | |
|---|---|---|
| Market Cap | $1.00 billion | $57.94 billion |
| Revenue (TTM) | — | $2.23 billion |
| Net Income (TTM) | $-88,531,000 | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| CADL | MRNA | |
|---|---|---|
| Price / Book | 7.97 | 8.57 |
| Price / Sales | — | 26.01 |
CADL leads on 1 of 1 valuation factors.
Profitability
| CADL | MRNA | |
|---|---|---|
| Net Margin | — | -141.43% |
| Return on Equity | -70.19% | -46.61% |
MRNA leads on 1 of 1 profitability factors.
Risk & Sentiment
| CADL | MRNA | |
|---|---|---|
| Short Interest | 0.04% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: CADL overview, CADL financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.